Synergism of ciprofloxacin and trimethoprim against Salmonella enterica serovar typhi isolates showing reduced susceptibility to ciprofloxacin

Chemotherapy

Volumn 50, Issue 3, 2004, Pages 152-154

  Mandal, Shyamapada ^a   Mandal, Manisha Deb ^a   Pal, Nishith Kumar ^a  

^a CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Ciprofloxacin trimethoprim synergism; Salmonella enterica serovar typhi

Indexed keywords

CIPROFLOXACIN; TRIMETHOPRIM;

ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG POTENTIATION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEROTYPE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; SALMONELLA TYPHI; TRIMETHOPRIM;

EID: 3242757437     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077890     Document Type: Article

References (16)

1. Mandal S, Deb Mandal M, Pal NK: Antibiotic resistance pattern of Salmonella typhi isolates in Kolkata, India, during 1991-2001: A retrospective study. Jpn J Infect Dis 2002;55:58-59.
2. Campos LC, Dos Reis EM, Ribeiro Dias JC: In vitro susceptibility of Salmonella to ciprofloxacin and pefloxacin compared with three other antibiotics. Chemotherapy 1990;36:29-32.
3. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Laceys S: Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999;353:1590-1591.
4. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ: Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003;47:827-829.
5. Threlfall EJ, Skinner JA, Ward LR: Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi A. J Antimicrob Chemother 2001;48:740-741.
6. Huovinen P, Wolfson JS, Hooper DC: Synergism of trimethoprim and ciprofloxacin against clinical bacterial isolates. Eur J Clin Microbiol Infect Dis 1992;11:255-257.
7. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically, ed 4. Approved standard M7-A4. Wayne, National Committee for Clinical Laboratory Standards, 1997.
8. Krogstad DJ, Moellering RC: Combinations of antibiotics, mechanisms of interaction against bacteria; in Lorian V (ed): Antibiotics in Laboratory Medicine. Baltimore, Williams & Wilkins, 1980, pp 298-341.
9. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J: Effects of combinations of β-lactams, daptomycin, gentamycin and glycopeptides against glycopeptide-resistant Enterococci. Antimicrob Agents Chemother 1991;35:92.
10. Genedani S, Castelli M, Foresta P, Bertolini A: Oxolinic acid-trimethoprim combination: Effects on DNA synthesis and on viability of Escherichia coli. Chemotherapy 1983;29:24-27.
11. Bertolini A, Castelli M, Genedani S, Garuti M: Trimethoprim enhances the antimicrobial activity of nalidixic acid and oxolinic acid and delays the emergence of resistance. Experimentia 1980;36:243-244.
12. Snyder MJ, Perroni J, Gonzalez O, Palomino C, Gonzalez C, Music S, Dupont HL, Hornick RB, Woodward TE: Trimethoprim-sulfamethoxazole in the treatment of typhoid and paratyphoid fevers. J Infect Dis 1973;128:S734-S737.
13. Datta N, Richards H, Datta C: Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet 1981;i:1181-1183.
14. Kumar PD, Ray P, Sengal R: Ciprofloxacin for typhoid fever. Lancet 1991;338:1143.
15. Graninger W, Zedtwitz-Liebenstein K, Laferl H, Burgmann H: Quinolones in gastrointestinal infections. Chemotherapy 1996;42(suppl 1):43-53.
16. Murdoch DH, Banatvala NA, Bone A, Shoismatulloev BI, Ward LR, Threlfall EJ: Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 1998;351:339.